Study | hsCRP | TNF-α | IL-1 | IL-6 | sICAM-1 | sVCAM-1 |
---|
 | μg/ml | pg/ml | pg/ml | pg/ml | pg/ml | pg/ml |
---|
Mehra 2006
| NR | 1.5 | NR | NR | NR | NR |
O'Keefe 2006
| 1.3 | 6.7 | NR | 1.6 | NR | NR |
Nodari 2009
| NR | 19.0 | 402.0 | 7.15 | NR | NR |
Zhao 2009
| 5.6 | 61.5 | NR | 11.3 | 1.0 | 1.6 |
Eschen 2010
| 2.1 | NR | NR | NR | 0.3 | 0.7 |
Moertl 2011 a
| 5.0 | 2.5 | NR | 3.7 | NR | NR |
Moertl 2011 b
| 5.0 | 2.3 | NR | 3.2 | NR | NR |
Nodari 2011
| NR | 23.0 | 483.0 | 10.6 | NR | NR |
- The study by Moertl et al. includes two intervention groups of different dosages of EPA + DHA (Moertl 2011a, EPA + DHA 840 mg/day and Moertl 2011b, EPA + DHA 3360 mg/day).
- hsCRP, high sensitivity C reactive protein; TNF-α, tumor necrosis factor α; IL-1, interleukin 1; IL-6, interleukin 6; sICAM-1, soluble intracellular adhesion molecule-1; sVCAM-1, soluble vascular cell adhesion molecule-1; NR, not reported.